From a pathophysiological perspective, however, STBEVs could have detrimental effects in women that have pre-existing (potentially subclinical) disease associated with increased vascular LOX-1 expression, such as in hypertension, diabetes, atherosclerosis or dyslipidaemia10–12. Here, OLR1 is linked to Hypertension.